European Medicines Agency issues positive opinion on application for orphan designation of nomacopan for bullous pemphigoid

Nomacopan is a dual inhibitor of C5 and LTB4. In a Phase II study, 7 of 9 treated patients showed a rapid and clinically significant reduction in Bullous Pemphigoid Disease Area Index score (no specific results reported). It was granted orphan drug designation in the US in 2019.


Biospace Inc.